CD52 and Miyoshi myopathy: This approach is hypothesized to overcome some of the challenges experienced with traditional CAR T therapy, such as the potentially long time between apheresis and product manufacturing.The UNIVERSAL study was the first-in-Human Phase I Trial of Allo-CAR T-Cell Therapy with ALLO-715 (Anti-BCMA) and ALLO-647 (Anti-CD52) in patients with R/R MM [63].